500
Participants
Start Date
December 10, 2019
Primary Completion Date
June 29, 2020
Study Completion Date
December 31, 2027
LY3484356
Administered orally
Abemaciclib
Administered orally
Everolimus
Administered orally
Alpelisib
Administered orally
Trastuzumab
Administered intravenously
Aromatase Inhibitor (AI)
Anastrozole or Exemestane or Letrozole administered orally (physician choice)
Pertuzumab
Administered intravenously
National Cheng-Kung Uni. Hosp., Tainan City
Institut Jules Bordet, Anderlecht
St Vincent's Hospital Sydney, Darlinghurst
Calvary Mater Newcastle, Waratah
Antwerp University Hospital, Edegem
UZ Leuven, Leuven
Cancer Research SA, Adelaide
Breast Cancer Research Centre-WA, Nedlands
Linear Clinical Research, Nedlands
National Taiwan University Hospital, Taipei
Memorial Sloan Kettering Cancer Center, New York
Mackay Memorial Hospital, Taipei
Taipei Veterans General Hospital, Taipei
Memorial Sloan Kettering Cancer Center, Commack
Wilmot Cancer Institute, Rochester
UPMC Hillman Cancer Center Harrisburg, Harrisburg
Johns Hopkins University, Baltimore
Inova Schar Cancer Institute, Fairfax
Duke University, Durham
Hospital General Universitario Gregorio Marañon, Madrid
Hospital Universitario Ramón y Cajal, Madrid
Hospital Clinico San Carlos, Madrid
Hospital Universitario Fundación Jiménez Díaz, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario HM Sanchinarro, Madrid
Winship Cancer Center Emory University, Atlanta
Mayo Clinic in Florida, Jacksonville
Lake Nona DDU, Orlando
Vanderbilt Health One Hundred Oaks, Nashville
SCRI Oncology Partners, Nashville
Tennessee Oncology Nashville, Nashville
China Medical University Hospital, Taichung
Ohio State University Medical Center, Columbus
Fundación Instituto Valenciano de Oncología, Valencia
Hospital Clínico Universitario de Valencia, Valencia
Community Cancer Center North, Indianapolis
Minnesota Oncology/Hematology PA, Minneapolis
Mayo Clinic, Rochester
Washington University, St Louis
Institut de cancérologie Strasbourg Europe (ICANS), Strasbourg
Highlands Oncology Group, Springdale
University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City
Institut Curie, Paris
Texas Oncology - Tyler, Tyler
Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas
Minnesota Oncology/Hematology PA, The Woodlands
Oncology and Hematology Associates of Southwest Virginia Inc, The Woodlands
Texas Oncology - San Antonio Medical Center, The Woodlands
US Oncology, The Woodlands
USO-Rocky Mountain Cancer Center, The Woodlands
Kaohsiung Medical University Hospital, Kaohsiung City
Mayo Clinic in Arizona - Phoenix, Phoenix
Banner MD Anderson Cancer Center, Gilbert
Beverly Hills Cancer Center, Beverly Hills
University of California, Irvine, Orange
UCSF Medical Center at Mission Bay, San Francisco
Asante Rogue Regional Medical Center, Medford
Seattle Cancer Care Alliance, Seattle
Massachusetts General Hospital, Boston
Dana-Farber Cancer Institute, Boston
Memorial Sloan Kettering - Bergen, Montvale
Rhode Island Hospital, Providence
UT Southwestern Med Center, Dallas
University of Texas MD Anderson Cancer Center, Houston
South Texas Accelerated Research Therapeutics (START), San Antonio
The University of Vermont Medical Center Inc., Burlington
Hyogo Cancer Center, Akashi
National Cancer Center Hospital, Chuo-ku
Severance Hospital, Yonsei University Health System, Seoul
Seoul National University Hospital, Seoul
Asan Medical Center, Seoul
Samsung Medical Center, Seoul
Hospital Clínic de Barcelona, Barcelona
Hospital Universitari Vall d'Hebron, Barcelona
Eli Lilly and Company
INDUSTRY